Viralytics Ltd SP Ad (VRACY) 1.9600 $VRACY
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.63 (+0.26), ACH: 7.53 (+0.02), CYTR: 2.36 (+0.06), AVEO: 0.94 (-0.03), ARQL: 1.79 (+0.05), CTIC: 0.39 (-0.03), ARRY: 3.26 (+0.01)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 8.38 (+0.18), EBS: 41.08 (-0.08), ARWR: 5.93 (+0.12), AMBX: (), PFE: 34.75 (-0.04), ADMP: 3.09 (unch), AMGN: 152.30 (+0.40), LLY: 74.25 (+0.54), BIND: 0.42 (-0.01), GSK: 40.57 (+0.53), BMY: 71.73 (-0.84), MDVN: 59.36 (-0.18), PGNX: 4.74 (+0.11), GTXI: 0.63 (-0.02), AZN: 27.63 (+0.26), NLNK: 10.67 (+0.36), ABBV: 60.90 (+0.50)
Viralytics Completes $28 million Placement -- SPP to Follow
PR Newswire - Mon Dec 14, 5:00AM CST
Viralytics Limited (Viralytics) announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736. The placement was significantly oversubscribed with strong demand from international specialist healthcare investment funds, including two New York based Funds who are new to the register. The price represents a 5.2% discount to the VWAP for the 5 days up to and including 9 December 2015.
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015 - 15 Companies & 21 Drug Profiles
M2 - Mon Dec 07, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/s7bjp9/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - APIM Therapeutics AS - Astellas Pharma Inc. - Bavarian Nordic A/S - BioCancell Ltd - Celgene Corporation - Cold Genesys, Inc. - Heat Biologics, Inc. - Spectrum Pharmaceuticals, Inc. - TARIS BioMedical, Inc. - Telesta Therapeutics Inc. - Telormedix SA - Vakzine Projekt Management GmbH - Viralytics Ltd. - Viventia Biotechnologies Inc. Drug Profiles - ALT-801 - ALT-803 - apaziquone - APL-1202 - ATX-101 - BC-819 - Biologic for Superficial Bladder Cancer - CG-0070 - CV-301 - CVA-21 - DAB-389EGF - docetaxel - Drug for NMIBC - erlotinib hydrochloride - imiquimod - lenalidomide - mitomycin SR - Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - oportuzumab monatox - rAd-IFN - sirolimus albumin-bound - TD-210 - Urocidin - vesigenurtucel-L - VPM-1002 For more information visit http://www.researchandmarkets.com/research/s7bjp9/non_muscle
HTBX: 0.60 (unch), SPPI: 6.82 (unch), CELGZ: 1.33 (-0.07)
Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK(TM) and KEYTRUDA(R) in Lung and Bladder Cancer
PR Newswire - Fri Nov 06, 5:00AM CST
Viralytics Limited (ASX: VLA, OTC: VRACY) announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK(TM), with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.
MRK: 57.50 (+1.41)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 80.80 (-3.21), CLDX: 4.41 (+0.16), CYCC: 5.33 (-0.43), IMMU: 2.81 (-0.16), EBS: 41.08 (-0.08), INCY: 80.00 (+0.55), TGTX: 7.39 (+0.38), AMGN: 152.30 (+0.40), LLY: 74.25 (+0.54), BMY: 71.73 (-0.84), GILD: 83.51 (+0.47), CELGZ: 1.33 (-0.07)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.63 (+0.26), ACH: 7.53 (+0.02), CYTR: 2.36 (+0.06), AVEO: 0.94 (-0.03), ARQL: 1.79 (+0.05), CTIC: 0.39 (-0.03), ARRY: 3.26 (+0.01)
World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 8.38 (+0.18), EBS: 41.08 (-0.08), ARWR: 5.93 (+0.12), AMBX: (), PFE: 34.75 (-0.04), ADMP: 3.09 (unch), AMGN: 152.30 (+0.40), LLY: 74.25 (+0.54), BIND: 0.42 (-0.01), GSK: 40.57 (+0.53), BMY: 71.73 (-0.84), MDVN: 59.36 (-0.18), PGNX: 4.74 (+0.11), GTXI: 0.63 (-0.02), AZN: 27.63 (+0.26), NLNK: 10.67 (+0.36), ABBV: 60.90 (+0.50)
Viralytics Completes $28 million Placement -- SPP to Follow
PR Newswire - Mon Dec 14, 5:00AM CST
Viralytics Limited (Viralytics) announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736. The placement was significantly oversubscribed with strong demand from international specialist healthcare investment funds, including two New York based Funds who are new to the register. The price represents a 5.2% discount to the VWAP for the 5 days up to and including 9 December 2015.
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015 - 15 Companies & 21 Drug Profiles
M2 - Mon Dec 07, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/s7bjp9/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - APIM Therapeutics AS - Astellas Pharma Inc. - Bavarian Nordic A/S - BioCancell Ltd - Celgene Corporation - Cold Genesys, Inc. - Heat Biologics, Inc. - Spectrum Pharmaceuticals, Inc. - TARIS BioMedical, Inc. - Telesta Therapeutics Inc. - Telormedix SA - Vakzine Projekt Management GmbH - Viralytics Ltd. - Viventia Biotechnologies Inc. Drug Profiles - ALT-801 - ALT-803 - apaziquone - APL-1202 - ATX-101 - BC-819 - Biologic for Superficial Bladder Cancer - CG-0070 - CV-301 - CVA-21 - DAB-389EGF - docetaxel - Drug for NMIBC - erlotinib hydrochloride - imiquimod - lenalidomide - mitomycin SR - Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - oportuzumab monatox - rAd-IFN - sirolimus albumin-bound - TD-210 - Urocidin - vesigenurtucel-L - VPM-1002 For more information visit http://www.researchandmarkets.com/research/s7bjp9/non_muscle
HTBX: 0.60 (unch), SPPI: 6.82 (unch), CELGZ: 1.33 (-0.07)
Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK(TM) and KEYTRUDA(R) in Lung and Bladder Cancer
PR Newswire - Fri Nov 06, 5:00AM CST
Viralytics Limited (ASX: VLA, OTC: VRACY) announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK(TM), with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.
MRK: 57.50 (+1.41)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 80.80 (-3.21), CLDX: 4.41 (+0.16), CYCC: 5.33 (-0.43), IMMU: 2.81 (-0.16), EBS: 41.08 (-0.08), INCY: 80.00 (+0.55), TGTX: 7.39 (+0.38), AMGN: 152.30 (+0.40), LLY: 74.25 (+0.54), BMY: 71.73 (-0.84), GILD: 83.51 (+0.47), CELGZ: 1.33 (-0.07)
